A Randomized, Open-Label, Controlled, Multi-Center Phase III Clinical Study of Camrelizumab Combined With Famitinib Malate Versus Platinum-based Chemotherapy in the Treatment of Recurrent/Metastatic Cervical Cancer
Latest Information Update: 05 Jun 2023
At a glance
- Drugs Camrelizumab (Primary) ; Famitinib (Primary) ; Antineoplastics
- Indications Carcinoma; Cervical cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 12 Dec 2021 Status changed from not yet recruiting to recruiting.
- 01 Jun 2021 New trial record